These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 38606512)

  • 1. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).
    Yongprayoon V; Wattanakul N; Khomate W; Apithanangsiri N; Kasitipradit T; Nantajit D; Tavassoli M
    Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38606512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms.
    Tang J; Chen H; Fan H; Chen T; Pu C; Guo Y
    Bioorg Med Chem; 2024 Nov; 113():117929. PubMed ID: 39317007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
    Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
    Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-induced suppression of HPV E6/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma.
    Nantajit D; Presta L; Sauter T; Tavassoli M
    Cell Death Dis; 2022 Nov; 13(11):921. PubMed ID: 36333293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.
    Wu Y; Wang Y; Diao P; Zhang W; Li J; Ge H; Song Y; Li Z; Wang D; Liu L; Jiang H; Cheng J
    Theranostics; 2019; 9(6):1777-1793. PubMed ID: 31037138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.
    Cai H; Liang J; Jiang Y; Wang Z; Li H; Wang W; Wang C; Hou J
    J Exp Clin Cancer Res; 2024 Mar; 43(1):69. PubMed ID: 38443991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.
    Chen N; Golczer G; Ghose S; Lin B; Langenbucher A; Webb J; Bhanot H; Abt NB; Lin D; Varvares M; Sattler M; Egloff AM; Joh R; Uppaluri R; Emerick KS; Lawrence MS; Saladi SV
    Cell Rep; 2022 Jun; 39(11):110970. PubMed ID: 35705032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
    Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
    Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer.
    Zhang S; Lai Y; Pan J; Saeed M; Li S; Zhou H; Jiang X; Gao J; Zhu Y; Yu H; Zhang W; Xu Z
    Adv Mater; 2024 Jun; 36(23):e2314132. PubMed ID: 38353332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma.
    Zhang M; Wang G; Ma Z; Xiong G; Wang W; Huang Z; Wan Y; Xu X; Hoyle RG; Yi C; Hou J; Liu X; Chen D; Li J; Wang C
    Mol Ther; 2022 Nov; 30(11):3394-3413. PubMed ID: 35923111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 14. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma.
    Dong J; Li J; Li Y; Ma Z; Yu Y; Wang CY
    Nat Commun; 2021 Jun; 12(1):3974. PubMed ID: 34172737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain inhibitors and therapeutic applications.
    Gajjela BK; Zhou MM
    Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene.
    Yamamoto T; Hirosue A; Nakamoto M; Yoshida R; Sakata J; Matsuoka Y; Kawahara K; Nagao Y; Nagata M; Takahashi N; Hiraki A; Shinohara M; Nakao M; Saitoh N; Nakayama H
    Br J Cancer; 2020 Aug; 123(4):580-590. PubMed ID: 32499570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of BRD4 in Gastric Cancer and its Clinical Significance as a Novel Therapeutic Target.
    Zhang M; Huang H; Wei M; Sun M; Deng G; Hu S; Wang H; Gong Y
    Curr Cancer Drug Targets; 2024; 24(2):167-177. PubMed ID: 37282642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
    Gold S; Shilatifard A
    Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
    Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida LO
    Arch Oral Biol; 2022 Sep; 141():105468. PubMed ID: 35679799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.